TGTX Revenue Per Share from 2010 to 2025

TGTX Stock  USD 29.55  0.41  1.41%   
TG Therapeutics Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share will likely drop to 1.80 in 2025. Revenue Per Share is the amount of revenue generated by TG Therapeutics per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
1.89
Current Value
1.8
Quarterly Volatility
120.68445861
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 510.8 K, Interest Expense of 15.2 M or Total Revenue of 282.1 M, as well as many indicators such as Price To Sales Ratio of 8.87, Dividend Yield of 4.0E-4 or PTB Ratio of 14.28. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of TG Therapeutics over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. TG Therapeutics' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 1.82910 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

TGTX Revenue Per Share Regression Statistics

Arithmetic Mean30.53
Geometric Mean0.02
Coefficient Of Variation395.26
Mean Deviation56.57
Median0
Standard Deviation120.68
Sample Variance14,565
Range483
R-Value(0.42)
Mean Square Error12,900
R-Squared0.17
Significance0.11
Slope(10.55)
Total Sum of Squares218,471

TGTX Revenue Per Share History

2025 1.8
2024 1.89
2023 1.65
2022 0.0206
2021 0.0506
2020 0.001318
2019 0.00172

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 1.89  1.80 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.